Emergent BioSolutions Announces Preliminary 2012 Financial Results and
Provides Guidance for 2013
ROCKVILLE, Md. -- January 7, 2013
Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary 2012
financial results and provided guidance for 2013.
For 2012, the company anticipates total revenues of $280 to $284 million,
which includes approximately $216 million of product sales and $64 to $68
million of contracts and grants revenue. The company also anticipates 2012 net
income of $21 to $24 million, which includes a one-time, non-cash charge of
$9.6 million related to impairment of in-process research and development
associated with the SBI-087 product candidate, which was being developed by
Pfizer; the impairment charge was incurred in Q1 2012. In addition, the
company anticipates year end 2012 cash and cash equivalents combined with
accounts receivable of approximately $235 million.
Product revenues for 2012 are primarily attributable to delivery of
approximately 8.1 million doses of BioThrax^® (Anthrax Vaccine Adsorbed) to
CDC during the year. Contracts and grants revenue for 2012 is primarily
attributable to revenues from our contracts with BARDA for large-scale
manufacturing of BioThrax and for development of PreviThrax^TM (Recombinant
Protective Antigen Anthrax Vaccine, Purified).
For 2013, the company forecasts total revenues of $290 to $310 million, split
between product sales of $230 to $240 million and contracts and grants revenue
of $60 to $70 million. The company also forecasts 2013 net income of $20 to
$30 million. The 2013 forecast does not reflect the impact of a possible M&A
Daniel J. Abdun-Nabi, president and chief executive officer of Emergent
BioSolutions Inc., stated, “The 2012 preliminary financial performance is in
line with our expectations and guidance. During 2013, we will be focused on
implementing the principles outlined in our growth plan, including
streamlining our R&D efforts and executing on our M&A strategy, as we drive
towards achieving our stated 2015 financial and operational goals.”
The 2012 financial results will be finalized upon the completion of the
company’s external audit, which is anticipated in early March 2013.
About Emergent BioSolutions Inc.
Emergent BioSolutions is a specialty pharmaceutical company seeking to protect
and enhance life by offering specialized products to healthcare providers and
governments to address medical needs and emerging health threats. Additional
information about us may be found at www.emergentbiosolutions.com.
Follow us on twitter: @emergentbiosolu.
This press release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Any statements, other
than statements of historical fact, including statements regarding our
strategy, future operations, future financial position, future revenues,
projected costs, prospects, plans and objectives of management, including our
expected revenue growth and net income, and any other statements containing
the words “believes”, “expects”, “anticipates”, “intends”, “plans”,
“estimates” and similar expressions, are forward-looking statements. These
forward-looking statements are based on our current intentions, beliefs and
expectations regarding future events. We cannot guarantee that any
forward-looking statement will be accurate. Investors should realize that if
underlying assumptions prove inaccurate or unknown risks or uncertainties
materialize, actual results could differ materially from our expectations.
Investors are, therefore, cautioned not to place undue reliance on any
forward-looking statement. Any forward-looking statement speaks only as of the
date of this press release, and, except as required by law, we do not
undertake to update any forward-looking statement to reflect new information,
events or circumstances.
There are a number of important factors that could cause the company’s actual
results to differ materially from those indicated by such forward-looking
statements, including appropriations for BioThrax^® procurement; our ability
to obtain new BioThrax^® sales contracts; our plans to pursue label expansions
and improvements for BioThrax^®; our ability to identify and acquire or in
license products and product candidates that satisfy our selection criteria;
the potential benefits of our existing collaboration agreements and our
ability to enter into selective additional collaboration arrangements; our
ability to expand our manufacturing facilities and capabilities; the rate and
degree of market acceptance and clinical utility of our products; the success
of our ongoing and planned development programs; the timing of and our ability
to obtain and maintain regulatory approvals for our product candidates; and
our commercialization, marketing and manufacturing capabilities and strategy.
The foregoing sets forth many, but not all, of the factors that could cause
actual results to differ from our expectations in any forward-looking
statement. Investors should consider this cautionary statement, as well as the
risk factors identified in our periodic reports filed with the SEC, when
evaluating our forward-looking statements.
Emergent BioSolutions Inc.
Robert G. Burrows, 301-795-1877
Vice President, Investor Relations
Tracey Schmitt, 301-795-1800
Vice President, Corporate Communications
Press spacebar to pause and continue. Press esc to stop.